Boston, MA -- (SBWIRE) -- 04/28/2016 -- The Global Drug Delivery Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest Drug Delivery agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Drug Delivery partnering deals.

The report presents financial deal term values for Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Drug Delivery partnering field; both the leading deal values and most active Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

Get More Details on this Report and a Full Table of Contents at Global Drug Delivery Partnering 2010-2016: Deal trends, players and financials

One of the key highlights of the report is that over 1,800 online deal records of actual Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format ? by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered ? contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Drug Delivery dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Drug Delivery deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Drug Delivery deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Drug Delivery partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Drug Delivery partnering deals signed and announced since Jan 2010. The chapter is organized by specific Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Drug Delivery partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Drug Delivery technologies and products.

Key benefits

Global Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Drug Delivery deal trends since 2010
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Drug Delivery agreements with numerous real life case studies
Detailed access to actual Drug Delivery contracts entered into by leading biopharma companies
Identify most active Drug Delivery dealmakers since 2010
Insight into terms included in a Drug Delivery partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:
-Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts
-Global Transdermal Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts
-Global Injectable Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts
-Global Topical Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts
-Global Oncology Partnering 2010-2016: Deal trends, players and financials